Results 1 to 10 of about 169,813 (342)

Movement Disorders and Hematologic Diseases. [PDF]

Mov Disord Clin Pract, 2021
AbstractBackgroundMovement disorders can be associated with or caused by hematological abnormalities. The objective of this review is to highlight features that will aid in the clinician's recognition and treatment of these disorders.MethodsMESH terms relevant to movement disorders and hematologic diseases were searched to identify conditions included ...
Patel RA, Hall DA, Eichenseer S, Bailey M.   +3 more
europepmc   +4 more sources

Hematological Diseases and Osteoporosis [PDF]

International Journal of Molecular Sciences, 2020
Secondary osteoporosis is a common clinical problem faced by bone specialists, with a higher frequency in men than in women. One of several causes of secondary osteoporosis is hematological disease. There are numerous hematological diseases that can have a deleterious impact on bone health.
Gaudio A., Xourafa A., Rapisarda R., Zanoli L., Signorelli S. S., Castellino P.   +5 more
openaire   +2 more sources

CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia

Experimental Hematology & Oncology, 2022
Relapsed/refractory acute myeloid leukemia (AML) patients generally have a dismal prognosis and the treatment remains challenging. Due to the expression of CD7 on 30% AML and not on normal myeloid and erythroid cells, CD7 is an attractive target for ...
Xuanqi Cao, Haiping Dai, Qingya Cui, Zheng Li, Wenhong Shen, Jinlan Pan, Hongjie Shen, Qinfen Ma, Mengyun Li, Sifan Chen, Juncheng Chen, Xiaming Zhu, Huimin Meng, Lin Yang, Depei Wu, Xiaowen Tang   +15 more
doaj   +1 more source

Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?

Blood Cancer Journal, 2023
CD19 chimeric antigen receptor (CAR) T-cell therapy has shown great success against B-cell acute lymphoblastic leukemia (B-ALL). Tandem and sequential CD19/CD22 dual-target CAR T-cell therapies have been developed to reduce the possibility of CD19 ...
Sining Liu, Xinyue Zhang, Haiping Dai, Wei Cui, Jia Yin, Zheng Li, Xiao Yang, Chunxiu Yang, Shengli Xue, Huiying Qiu, Miao Miao, Suning Chen, Zhengming Jin, Chengcheng Fu, Caixia Li, Aining Sun, Yue Han, Ying Wang, Lei Yu, Depei Wu, Qingya Cui, Xiaowen Tang   +21 more
doaj   +1 more source

Clinical characteristics and prognostic significance of DNA methylation regulatory gene mutations in acute myeloid leukemia

Clinical Epigenetics, 2023
Background DNA methylation is a form of epigenetic modification that regulates gene expression. However, there are limited data on the comprehensive analysis of DNA methylation regulated gene mutations (DMRGM) in acute myeloid leukemia (AML) mainly ...
Xiaoyan Xu, Hong Wang, Haohao Han, Yifang Yao, Xueqian Li, Jiaqian Qi, Chengsen Cai, Meng Zhou, Yaqiong Tang, Tingting Pan, Ziyan Zhang, Jingyi Yang, Depei Wu, Yue Han   +13 more
doaj   +1 more source

Hope for hematological diseases [PDF]

Science, 2020
Tweaking growth media helps cultured hematopoietic stem cells ...
openaire   +2 more sources

Decitabine in combination with fludarabine and cyclophosphamide as a lymphodepletion regimen followed by CD19/CD22 bispecific targeted CAR T-cell therapy significantly improves survival in relapsed/refractory B-ALL patients

Experimental Hematology & Oncology, 2023
Relapse is a major limitation of chimeric antigen receptor (CAR) T-cell therapy. Here, we speculated that decitabine (DAC) in combination with fludarabine and cyclophosphamide (FC) as a lymphodepletion regimen may improve the efficacy of CD19/CD22 CAR T ...
Yunju Ma, Haiping Dai, Qingya Cui, Sining Liu, Liqing Kang, Xiaying Lian, Wei Cui, Jia Yin, Lingling Liu, Mengjie Cai, Lei Yu, Depei Wu, Xiaowen Tang   +12 more
doaj   +1 more source

Microbiota and Hematological Diseases

International Journal of Hematology-Oncology and Stem Cell Research, 2022
The microbiota is directly involved in the host metabolic process, as well as in immune response modulation and recruitment of different cells typology in the inflammatory site. Human microbiota modification (dysbiosis) is a condition which could be correlated with various pathologies.
openaire   +3 more sources

DLC1 deficiency at diagnosis predicts poor prognosis in acute myeloid leukemia

Experimental Hematology & Oncology, 2022
Acute myeloid leukemia (AML) is a complex, heterogeneous malignant hematologic disease. Although multiple prognostic-related genes gave been explored in previous studies, there are still many genes whose prognostic value remains unclear. In this study, a
Xueqian Li, Jiaqian Qi, Xiaofei Song, Xiaoyan Xu, Tingting Pan, Hong Wang, Jingyi Yang, Yue Han   +7 more
doaj   +1 more source

Roles of the intestinal microbiota and microbial metabolites in acute GVHD

Experimental Hematology & Oncology, 2021
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is one of the most curative strategies for the treatment of many hematologic malignancies and diseases. However, acute graft-versus-host disease (GVHD) limits the success of allo-HSCT.
Dandan Lin, Bo Hu, Pengfei Li, Ye Zhao, Yang Xu, Depei Wu   +5 more
doaj   +1 more source